A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

This study tests SHR-1826 — a new investigational drug — either alone or in combination with other cancer treatments in people with non-small cell lung cancer (NSCLC), to assess its safety and effectiveness. **You may be eligible if...** - You are 18–75 years old with a confirmed diagnosis of NSCLC - You are in good health (ECOG 0–1) with at least 3 months expected survival - You have at least one measurable tumor - Your organ function (liver, kidney, blood) is adequate - You are willing to provide a tumor tissue sample **You may NOT be eligible if...** - Your cancer has spread to the brain lining (meningeal metastasis) - You have had another cancer or are currently being treated for one - You have active hepatitis B or C - You have a history of immune deficiency - You had major surgery within 28 days before starting treatment - You have uncontrolled severe cardiovascular disease - You had a severe infection within 30 days before the first dose Talk to your doctor to see if this trial is right for you.